• 1:中华预防医学会

摘要(Abstract)：

中国上市的脑膜炎球菌疫苗包括脑膜炎球菌多糖疫苗、脑膜炎球菌多糖结合疫苗和联合疫苗,不同生产企业的脑膜炎球菌多糖结合疫苗的免疫程序有所不同,给实际接种工作带来困扰。本共识结合国内外研究最新进展,基于流行性脑脊髓膜炎流行特征、脑膜炎奈瑟菌菌群分布以及中国脑膜炎球菌疫苗免疫原性和安全性等研究证据,提出脑膜炎球菌疫苗预防接种建议,供预防接种人员和疾病预防控制机构人员参考使用。

关键词(KeyWords)： 流行性脑脊髓膜炎;脑膜炎奈瑟菌;脑膜炎球菌疫苗;共识

Abstract:

Keywords:

基金项目(Foundation):

作者(Author):

参考文献(References)：

• [1]丹尼斯·卡斯伯,安东尼·福奇.哈里森感染性疾病,第3版:英文版[M].北京:北京联合出版公司,2017:466-475.KASPER DL,FAUCI AS.Harrison’s infectious diseases,third edition:English edition[M].Beijing:Beijing United Publishing Company,2017:466-475.
• [2]王萌,李艺星,李军宏,等.2009-2010年中国流行性脑脊髓膜炎疫情流行病学特征分析[J].疾病监测,2012,27(6):435-438.WANG Meng,LI Yixing,LI Junhong,et al.Epidemiology ofmeningococcal meningitis in China,2009-2010 season[J].Disease Surveillance,2012,27(6):435-438.
• [3]肖丽君,方艳辉,程露阳,等.脑膜炎奈瑟菌疫苗研制进展[J].微生物学免疫学进展,2006,34(1):58-60.XIAO Li jun,FANG Yanhui,CHENG Luyang,e t al.Development ofNeisser ia meningi t idis vaccine[J].Progress in Microbiology and Immunology,2006,34(1):58-60.
• [4]刘文婷,李军宏,宁桂军,等.中国2012~2014年流行性脑脊髓膜炎流行病学特征分析[J].中国疫苗和免疫,2016,22(2):149-152+179.L IU We n t i n g,LIYixing,LI Junhong,et al.Epidemiological cha ract e r is t ics ofme n ingococcal meningitis in China,2012-2014[J].Chinese Journal ofVaccines and Immunization,2016,22(2):149-152+179.
• [5]李军宏,李艺星,吴丹,等.中国2006~2014年流行性脑脊髓膜炎病例菌群分布特征及变迁趋势[J].中国疫苗和免疫,2015,21(5):481-485.LI Junhong,LI Yixing,WU Dan,et al.Epidemiological cha r a c t e r i s t ics ofme n ingococca l me n ingi t i s a nd switching trend ofserogroups ofNeisseria meningitidis in China,2006-2014[J].Chinese Journal ofVaccines and Immunization,2015,21(5):481-485.
• [6]JAFRI RZ,ALI A,MESSONNIER NE,et al.Global epidemiology ofinvasive meningococcal disease[J].Population Health Metrics,2013,11(1):1-9.
• [7]VYSE A,WOLTER JM,CHEN J,et al.Meningococcal disease in Asia:an under-recognized public health burden[J].Epidemiol Infect,2011,139(7):967-985.
• [8]邵祝军.中国流行性脑脊髓膜炎流行变异趋势[J].中华预防医学杂志,2013,47(10):891-893.SHAO Zh u ju n.Tr e n d o fe p i d emi c v a r i a t i o n o fmeningococcal meningitis in China[J].Chinese Journal ofPreventive Medicine,2013,47(10):891-893.
• [9]陈昌标,姜仁杰,马福宝,等.A群脑膜炎球菌多糖结合疫苗安全性和免疫原性观察[J].中国计划免疫,2006,12(5):403-405.CHEN Changbiao,JIANG Renjie,MA Fubao,et al.Studies on safety and immunogenicity ofgroup A meningococcal polysaccharide conjugate vaccine[J].Chinese Journal ofVaccines and Immunization,2006,12(5):403-405.
• [10]朱为,叶强,李荣成,等.A群脑膜炎球菌多糖结合疫苗在6月龄~5岁儿童中的安全性与免疫原性研究[J].中国疫苗和免疫,2008,14(6):485-488.ZHU Wei,YE Qiang,LI Rongcheng,et al.Study on safety and immunogenicity ofgroup A meningococcal polysaccharide conjugate vaccine to the children among 6months to 5 years old[J].Chinese Journal ofVaccines and Immunization,2008,14(6):485-488.
• [11]陶红,李亚楠,伍传宏,等.A+C群脑膜炎球菌多糖结合疫苗安全性和免疫原性研究[J].中国疫苗和免疫,2009,15(6):531-535.TAO Hong,LI Yanan,WU Chuanhong,et al.Study on safety and immunogenicity ofgroup A/C meningococcal polysaccharide conjugate vaccine[J].Chinese Journal ofVaccines and Immunization,2009,15(6):531-535.
• [12]郑佳,朱向国,刘刚,等.A群C群脑膜炎球菌多糖结合疫苗的免疫原性及免疫持久性观察[J].中国生物制品学杂志,2015,28(7):707-710.ZHENG J i a,ZHU Xi a n g g u o,LIU G a n g,e t a l.Immunogenicity and immune persistence ofgroups A&Cmeningococcal polysacchar ide con jugate vaccine[J].Chinese Journal ofBiologicals,2015,28(7):707-710.
• [13]何莉,李荣成,李亚南,等.A+C群脑膜炎球菌多糖疫苗安全性和免疫原性的研究[J].中华流行病学杂志,2007,28(5):422-425.HE Li,LI Rongcheng,LI Yanan,et al.Study on the safety and immunogenicity ofgroup A+C meningococcal pol ys a c c h a r id e v a c c i n e[J].Chi n es e J o u r n a l ofEpidemiology,2007,28(5):422-425.
• [14]秦才珍,王宏军,陶红,等.不同剂量A/C群脑膜炎球菌多糖结合疫苗免疫学效果评价[J].中国疫苗和免疫,2010,16(5):462-465.QIN Caizhen,WANG Hongjun,TAO Hong,et al.Study on immunogenicity between different doses ofgroup A/C meningococcal polysaccharide conjugate vaccine[J].Chinese Journal ofVaccines and Immunization,2010,16(5):462-465.
• [15]潘金仁,陈会红,李寿俊,等.A群C群脑膜炎球菌多糖结合疫苗6月龄儿童初次免疫效果[J].中国疫苗和免疫,2015,21(5):511-514.PAN J inren,CHEN Huihong,LI Shou jun,e t al.Immunogenicity ofgroup A and group C meningococcal con jugate vaccine after pr imary immunizat ion in children aged 6 months[J].Chinese Journal ofVaccines and Immunization,2015,21(5):511-514.
• [16]周海,李亚南,谈晔,等.A、C群脑膜炎球菌多糖结合疫苗免疫效果观察[J].中华预防医学杂志,2014,48(8):737-738.ZHOU Hai,LI Yanan,TAN Ye,et al.Observation on effect ofgroup A and group C meningococcal conjugate vaccine[J].Chinese Journal ofPreventive Medicine,2014,48(8):737-738.
• [17]徐鹭,路坚,丁筱竹.南京市健康儿童流脑A群和C群抗体水平监测及A+C群流脑疫苗免疫效果分析[J].现代预防医学,2009,36(11):2048-2049+2051.XU Lu,LU Jian,DING Xiaozhu.Monitoring on the ant ibody levels ofmeningi t is serogroup A and Cand immunization effect ofA and C meningococcal polysacchar ide vaccine among health childhood in Nanjing[J].Modern Preventive Medicine,2009,36(11):2048-2049+2051.
• [18]闫绍宏,张洪飞,刘天英,等.冻干A+C群脑膜炎球菌多糖疫苗安全性和免疫原性观察[J].微生物学免疫学进展,2009,37(2):16-18.YAN Shaohong,ZHANG Hongfei,LIU Tianying,et al.Observation on the safety and immunogenicity ofgroup A+C meningococcal polysaccharide vaccine[J].Progress in Microbiology and Immunology,2009,37(2):16-18.
• [19]张辉,胡树梅,姜强,等.ACYW135群脑膜炎球菌多糖疫苗的免疫原性评价[J].微生物学免疫学进展,2012,40(4):6-9.ZHANG Hui,HU Shumei,JIANG Qiang,et al.The immune effect ofgroup ACYW135 meningococcal polysaccharide vaccine[J].Progress in Microbiology and Immunology,2012,40(4):6-9.
• [20]伍传宏,王跃进,杭纪红,等.A、C、W135、Y群脑膜炎球菌四价多糖疫苗的安全性和免疫原性研究[J].实用预防医学,2007,14(6):1768-1770.WU Chuanhong,WANG Yuejin,HANG Jihong,et al.Study on safety and immunity ofgroup ACYW135meningococcal polysaccharide vaccine[J].Practical Preventive Medicine,2007,14(6):1768-1770.
• [21]李亚南,乔瑞洁,梁丽,等.2~59岁健康人群接种ACYW135群脑膜炎球菌多糖疫苗的免疫原性观察[J].微生物学免疫学进展,2012,40(5):15-19.L I Ya n a n,Q IAO R u i j i e,L IA NG L i,e t a l.Immunogenicity ofmeningococcal groups ACYW135polysaccharide vaccine inoculated in healthy population ofage 2-59 years old[J].Progress in Microbiology and Immunology,2012,40(5):15-19.
• [22]李亚南,梁丽,李艳萍,等.A、C群脑膜炎球菌-b型流感嗜血杆菌多糖结合疫苗免疫学效果观察[J].中国生物制品学杂志,2012,25(9):1190-1194+1197.LI Yanan,LIANG Li,LI Yanping,et al.Immune effect ofa meningococcal groups A&C Haemophilus influenzae type b conjugate vaccine[J].Chinese Journal ofBiologicals,2012,25(9):1190-1194+1197.
• [23]GARDNER P.Prevention ofmeningococcal disease[J].N Engl J Med,2006,355(5):1466-1473.
• [24]MACNEIL JR.Early estimate ofthe effectiveness ofquadrivalent meningococcal con jugate vaccine[J].The Pediatric Infectious Disease Journal,2011,30(6):451-455.
• [25]VESIKARI T,FORSTéN A,BOUTRIAU D,et al.A randomized study to assess the immunogenicity,ant ibody per sistence and safety ofa tet ravalent meningococcal serogroups A,C,W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years[J].Hum Vaccin Immunother,2012,8(12):1882-1891.
• [26]SAKOU I I,TZANAKAKI G,TSOLIA MN,et al.Investigation ofserum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose ofserogroup C meningococcal conjugate vaccine[J].Vaccine,2009,27(33):4408-4411.
• [27]WHO.Meningococcal meningitis[EB/OL].(2018-02-19)[(2018-12-26)].https://www.who.int/zh/news-room/factsheets/detail/meningococcal-meningitis.
• [28]汤妍,张吉凯,梁剑,等.A、C、Y、W135群脑膜炎球菌多糖疫苗安全性观察[J].热带医学杂志,2013,13(7):901-903.TANG Yan,ZHANG Jikai,LIANG Jian,et al.Safety oftetravalent meningococcal A,C,Y,W135 vaccine[J].Journal ofTropical Medicine,2013,13(7):901-903.
• [29]孟繁岳,庄菱,胡月梅,等.脑膜炎球菌多糖疫苗安全性及免疫原性评价[J].中国公共卫生,2010,26(12):1534-1536.MENG Fanyue,ZHUANG Ling,HU Yuemei,et al.Evaluation on safety and immunogenicity oftetravalent A/C/W135/Y meningococcal polysaccharide vaccine[J].Chinese Journal ofPublic Health,2010,26(12):1534-1536.
• [30]陈万庚,马永法,周爱庆.国产ACYW135流脑多糖疫苗免疫安全性观察[J].现代预防医学,2011,38(24):5131-5132.CHEN Wa n g e n g,MA Yo n g fa,ZHOU Ai q i n g.Observation on the safety ofdomestic ACYW135 group ofepidemic cerebrospinal meningitis polysaccharide vaccine[J].Modern Preventive Medicine,2011,38(24):5131-5132.
• [31]刘文英.A、C群脑膜炎球菌多糖结合疫苗在5-24月龄儿童中接种的安全性评价[J].中国医学前沿杂志(电子版),2015,7(2):65-67.LIU Wenying.Safety evaluation ofinoculation ofA,C meningococcal polysaccharide con jugate vaccine in children with age from 5 to 24 months[J].Chinese Journal ofthe Frontiers ofMedical Science(electronic version),2015,7(2):65-67.
• [32]章冰,王少芳,夏志才,等.宣城市A+C群脑膜炎球菌结合疫苗接种后不良反应观察[J].公共卫生与预防医学,2015,26(4):78-80.ZHANG Bing,WANG Shaofang,XIA Zhicai,et al.Observation ofadverse reactions ofgroup A+Cmeningococcal conjugate vaccine in Xuancheng city[J].Journal ofPublic Health and Preventive Medicine,2015,26(4):78-80.
• [33]李江嵘,杨军,刘晓强,等.AC群脑膜炎球菌(结合)b型流感嗜血杆菌(结合)联合疫苗上市后2~71月龄儿童接种的安全性研究[J].中国疫苗和免疫,2016,22(5):578-581.LI Jiangrong,YANG Jun,LIU Xiaoqiang,et al.Safety ofpost-market ing group A and C meningococcal conjugate and Haemophilus type b conjugate combined vaccine among children aged 2-71 months[J].Chinese Journal ofVaccines and Immunization,2016,22(5):578-581.
• [34]国家卫生计生委办公厅.国家免疫规划疫苗儿童免疫程序及说明(2016年版)[S].2016.General Office ofNational Health and Family Planning Commission.Childhood immunization schedules and instructions for vaccines ofthe national immunization program(2016 version)[S].2016.
• [35]MILLER L,ARAKAKI L,RAMAUTAR A,et al.Elevated risk for invasive meningococcal disease among persons with HIV[J].Ann Intern Med,2014,160(1):30-37.
• [36]SIMMONS RD,KIRWAN P,BEEBEEJAUN K,et al.Risk ofinvasive meningococcal disease in children and adults with HIV in England:a population-based cohort study[J].BMC Medicine,2015,13(1):297-305.
• [37]LUJA N-Z I LBERMA N N O,WAR SHAW MG,WILLIAMS PL,et al.Immunogenici ty and safety of1 vs 2 doses ofq uad r iva lent meningococca l con jugat e vaccine in youth infect ed wi th human immunodeficiency virus[J].The Journal ofPediatrics,2012,161(4):676-681.
• [38]Advisory Commi t tee on Immunizat ion Pract ices.Recommendations for use ofmeningococcal conjugate vaccines in HIV-infected persons-Advisory Committee on Immunization Practices,2016[J].Morbidity and Mortality Weekly Report,2016,65(43):1189-1194.
• [39]HAMMERQUIST RJ,Pharm D,et al.Vaccinations in asplenic adults[J].J Vaccinations,2016,73(9):220-228.
• [40]MEERVELD-EGGINK A,DE WEERDT O,DE VOERRM,et al.Impaired antibody response to conjugated meningococcal serogroup C vaccine in asplenic patients[J].Eur J Clin Microbiol Infect Dis,2011,30(5):611-618.
• [41]WHO.Meningococcal A con jugate vaccine:updated guidance,February 2015[J].Weekly Epidemiological Record,2015,90(8):57-68.
• [42]AZARIAS DAC,GIAMPAGLIA C,KIMURA H,et a l.Ma ternal and infant ant ibody response to meningococcal vaccinat ion in pregnancy[J].The Lancet,1977,310(8042):809-811.
• [43]MCCORMICK JB,GUSMAO HH,NAKAMURA S,et al.Antibody response to serogroup A and C meningococcal polysaccharide vaccines in infants born ofmothers vaccinated dur ing pregnancy[J].The Journal ofClinical Investigation,1980,65(5):1141.
• [44]SHIBL A,TUFENKEJI H,KHALIL M,et al.Consensus recommendation for meningococcal disease prevention for Ha j j and Umra pilgrimage/travel medicine[J].Eastern Mediterranean Health Journal,2013,19(4):389-392.
• [45]PAVL I A,K AT ER E LOS P,SME T I P,et al.Meningococcal vaccination for international travellers from Greece visiting developing countries[J].Travel Medicine and Infectious Disease,2016,14(3):261-26.
• [46]龚健,李翠云,董柏青,等.A+C群脑膜炎球菌多糖疫苗在C群流脑暴发中应急接种效果的研究[J].中华流行病学杂志,2008,29(6):552-555.GONG J ia n,LI Cuiy u n,DONG Ba iqing,e t a l.Effect iveness ofan immunizat ion campaign wit h group A and C meningococcal polysaccharide vaccine in controlling an outbreak ofgroup C meningococcal disease[J].Chinese Journal ofEpidemiology,2008,29(6):552-555.
• [47]SANTANI E L LO-NEWTON A,HUNTER PR.Ma nagemen t ofanout break ofmeningococca l meningitis in a Sudanese refugee camp in Northern Uganda[J].Epidemiol Infect,2000,124(1):75-81.
• [48]GOS SG E R N,SN A P E MD,Y U LM,e t a l.Immunogenici t y and tolerability ofrecombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules:a randomized cont rol led t r ial[J].The Journal ofthe Amer ican Medical Association,2012,307(6):573-582.
• [49]RICHMOND PC,MARSHALL HS,NISSEN MD.Safety,immunogenicity,and tolerability ofmeningococcal serogroup B bivalent recombinant lipoprotein 2086vaccine in healthy adolescents:a randomised,singleblind,placebo-cont rolled,phase 2 t r ial[J].Lancet Infectious Diseases,2012,12(8):597-607.